HCV Disease Progression
Treatment of Recurrent Hepatitis C after Liver Transplantation
- Details
- Category: Liver Transplant - HCV
- Published on Friday, 25 February 2011 03:47
- Written by Liz Highleyman
Hepatitis C patients with advanced liver disease may benefit from interferon-based therapy before receiving a liver transplant, but side effects are common and response rates are low, according to a systematic research review described in the January 2011 issue of Alimentary Pharmacology and Therapeutics. Injected antibodies do not prevent the new liver from becoming infected, but pegyalted interferon plus ribavirin can cures recurring HCV about 30% of the time.
HIV Coinfection Does Not Worsen Liver Transplant Outcomes in People with Hepatitis B or C
- Details
- Category: Decompensation & ESLD
- Published on Friday, 08 October 2010 12:46
- Written by Liz Highleyman
HIV positive liver transplant recipients with hepatitis B virus (HBV) or hepatitis C virus (HCV) coinfection did not fare worse overall than HIV negative people, according to a Spanish study presented at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2010) last month in Boston. Coinfected patients were less likely to experience organ rejection, but HCV recurrence was a leading cause of adverse outcomes.
Screening for Liver Cancer in HIV/HCV Coinfected People
- Details
- Category: Liver Cancer/HCC
- Published on Friday, 28 May 2010 23:40
- Written by Liz Highleyman
Nearly half of HIV/HCV coinfected individuals with liver cancer in an international study were never screened for hepatocellular carcinoma, but those who did undergo screening had their cancer detected at an earlier stage, leading to more effective treatment and improved survival, according to a report presented at the 45th Annual Meeting of the European Association for the Study of the Liver (EASL 2010) last month in Vienna.
Does CD4 Cell Count Influence Liver Fibrosis in HIV/HCV Coinfected People?
- Details
- Category: HCV Disease Progression
- Published on Friday, 01 October 2010 12:46
- Written by Liz Highleyman
Neither current nor lowest-ever CD4 T-cell levels were associated with hepatitis C virus (HCV) viral load or severity of liver fibrosis in HIV positive people after adjusting for other factors, according to a Spanish study presented at the recent 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2010) in Boston.
Rifaximin Reduces Encephalopathy Recurrence, Improves Quality of Life in People with Liver Cirrhosis
- Details
- Category: Decompensation & ESLD
- Published on Friday, 28 May 2010 20:23
- Written by Liz Highleyman
The broad-spectrum antibiotic rifaximin (Xifaxan) improves quality of life for people with liver cirrhosis who experience recurrent episodes of hepatic encephalopathy, or brain disease, according to research presented at the 45th Annual Meeting of the European Association for the Study of the Liver (EASL 2010) last month in Vienna. Another analysis from the same study indicated that rifaximin works by lowering the level of ammonia in the blood.
More Articles...
- EASL 2010: HIV/HCV Coinfected Patients with Acute Hepatitis C Are Equally Likely to Achieve Sustained Response with Interferon plus Ribavirin
- Chronic Hepatitis C Complications are Increasing, Especially among People Older than 60 Years
- Antibiotic Rifaximin Maintains Remission of Hepatic Encephalopathy in People with Advanced Liver Disease
- CROI 2010: Moderate Liver Fibrosis Predicts Disease and Death in HIV/HCV Coinfected People, but Successful Treatment Appears Protective
Web Design and Development by